... WhatsApp

Upadacitinib Helps Control Crohn’s and Colitis with Manageable Side Effects

You are here >> Home > Latest Updates > GI & HPB >Ulcerative Colitis> Upadacitinib…

Benefit-risk profile of Upadacitinib exploratory post hoc analysis of phase 2b3 studies in patients.DOI 10.1093ecco-jccjjaf198

Crohn’s disease and ulcerative colitis are two long-term illnesses that cause painful inflammation in the gut. Many people try different treatments before finding one that works. A new medicine called upadacitinib (UPA) is showing promise for those with moderate to severe symptoms.

This study looked at how well UPA works and how safe it is. It included people of different ages, health histories, and heart risk levels. Some had already tried other treatments without success.

The results showed that UPA helped more people feel better and stay in remission compared to those who took a placebo. Higher doses (30 mg daily) seemed to work even better than lower doses (15 mg).

Most people did not have major side effects. A few had more serious infections or shingles, especially in Crohn’s disease, but the overall risk remained low. The medicine didn’t raise the chances of heart problems or cancer.

This means UPA may be a good option for people with Crohn’s or colitis who haven’t responded to other treatments. It’s taken by mouth, which can be easier than injections.

If you have ongoing gut inflammation, talk to your doctor about whether UPA could be right for you.

 

Rate this post
Robotic Cancer Surgery
Best robotic cancer surgery in Ahmedabad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.